The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 …
Full TOIIW analysis →
Competitive advantage assessment
Key strengths
Operating Leverage in EffectOperating leverage is evident (score 0.90), with margins expanding over time.
Strong Liquidity BufferLiquidity position is strong (score 0.71), providing operational cushion.
Key risks
ROIC Below WACC or PeersROIC at 11.5th percentile suggests inefficient capital deployment.
Commodity Pressure / Weak DifferentiationGross margin at 21.6th percentile with high volatility suggests weak pricing power or commoditized products.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
The Oncology Institute, Inc. ranks #43 of 58
scored companies in Medical Care Facilities by moat score — the top 74%.
The widest moat in the group is Encompass Health Corporation (EHC)
at 77/100.
Moat scores for companies ranked near TOIIW in Medical Care Facilities
How TOIIW scores on the Corporate Default defenses
Pricing Power
Score 19
· 20% of the moat score
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 36
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 31
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 6
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 34
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 50
· 15% of the moat score
Scale matters only when it converts into economics.
What is The Oncology Institute, Inc.'s moat score?
The Oncology Institute, Inc. (TOIIW) scores 28 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #43 of 58 scored companies in Medical Care Facilities, the top 74%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 57 companies in Medical Care Facilities. Its strongest defense is Scale & Market Position (50/100) and its weakest is Capital Efficiency (6/100).
How does The Oncology Institute, Inc. compare with other Medical Care Facilities companies?
The Oncology Institute, Inc. ranks #43 of 58 scored companies in Medical Care Facilities by moat score. The widest moat in Medical Care Facilities is Encompass Health Corporation (EHC) at 77/100. The companies ranked closest are The Oncology Institute, Inc. (TOI) at 29 just above it and P3 Health Partners Inc. (PIII) at 28 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 57 companies in Medical Care Facilities. The defenses are then weighted to produce the overall score out of 100.
Why is The Oncology Institute, Inc. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for The Oncology Institute, Inc.?
The Corporate Default template measures 6 defenses, and TOIIW scores: Pricing Power (19), Cost Advantage (36), Customer Stickiness (31), Capital Efficiency (6), Resilience (34), Scale & Market Position (50). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.